Multi-omic and functional screening reveal targetable vulnerabilities in TP53 mutated multiple myeloma
View ORCID ProfileDimitrios Tsallos, Nemo Ikonen, View ORCID ProfileJuho J. Miettinen, Muntasir Mamun Majumder, Samuli Eldfors, Imre Västrik, Alun Parsons, Minna Suvela, Katie Dunphy, Paul Dowling, Despina Bazou, Peter O’Gorman, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, View ORCID ProfileCaroline A. Heckman
doi: https://doi.org/10.1101/2024.08.23.24312359
Dimitrios Tsallos
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
Nemo Ikonen
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
Juho J. Miettinen
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
Muntasir Mamun Majumder
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
Samuli Eldfors
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
2Massachusetts General Hospital Cancer Center, Charlestown, MA, and Department of Medicine, Harvard Medical School, Boston, MA, USA;
Imre Västrik
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
Alun Parsons
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
Minna Suvela
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
Katie Dunphy
3Department of Biology, Maynooth University, W23 F2K8, Maynooth, Ireland;
Paul Dowling
3Department of Biology, Maynooth University, W23 F2K8, Maynooth, Ireland;
Despina Bazou
4School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland;
Peter O’Gorman
5Department of Haematology, Mater Misericordiae University Hospital, D07 WKW8, Dublin, Ireland;
Juha Lievonen
6Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
Raija Silvennoinen
6Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
Pekka Anttila
6Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
Caroline A. Heckman
1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland;
Data Availability
The ex vivo drug sensitivity, DNA sequencing, RNA sequencing, and proteomic data generated in this study will be deposited in the Zenodo public repository upon acceptance of the manuscript for publication. Additionally, this study was supplemented with publicly available data from the Multiple Myeloma Research Foundation Researcher Gateway (https://research.themmrf.org/).
Posted August 23, 2024.
Multi-omic and functional screening reveal targetable vulnerabilities in TP53 mutated multiple myeloma
Dimitrios Tsallos, Nemo Ikonen, Juho J. Miettinen, Muntasir Mamun Majumder, Samuli Eldfors, Imre Västrik, Alun Parsons, Minna Suvela, Katie Dunphy, Paul Dowling, Despina Bazou, Peter O’Gorman, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Caroline A. Heckman
medRxiv 2024.08.23.24312359; doi: https://doi.org/10.1101/2024.08.23.24312359
Multi-omic and functional screening reveal targetable vulnerabilities in TP53 mutated multiple myeloma
Dimitrios Tsallos, Nemo Ikonen, Juho J. Miettinen, Muntasir Mamun Majumder, Samuli Eldfors, Imre Västrik, Alun Parsons, Minna Suvela, Katie Dunphy, Paul Dowling, Despina Bazou, Peter O’Gorman, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Caroline A. Heckman
medRxiv 2024.08.23.24312359; doi: https://doi.org/10.1101/2024.08.23.24312359
Subject Area
Subject Areas
- Addiction Medicine (375)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2767)
- Dermatology (237)
- Emergency Medicine (415)
- Epidemiology (12420)
- Forensic Medicine (10)
- Gastroenterology (785)
- Genetic and Genomic Medicine (4286)
- Geriatric Medicine (396)
- Health Economics (702)
- Health Informatics (2767)
- Health Policy (1025)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4063)
- Nursing (218)
- Nutrition (602)
- Oncology (2143)
- Ophthalmology (607)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (479)
- Pediatrics (1151)
- Primary Care Research (471)
- Public and Global Health (6667)
- Radiology and Imaging (1456)
- Respiratory Medicine (887)
- Rheumatology (425)
- Sports Medicine (353)
- Surgery (466)
- Toxicology (57)
- Transplantation (194)
- Urology (171)